Vital Patent milestone achieved– SVN 114

Solvonis Therapeutics PLC

03 September 2026

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Vital Patent milestone achieved- SVN 114

Composition-of-matter allowance strengthens proprietary position in a large and increasingly strategic PTSD market

LONDON - 3 September 2026 - Solvonis Therapeutics plc (LSE: SVNS), a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that the European Patent Office ("EPO") has issued a Notice of Allowance for composition-of-matter patent application EP 22730070.4, arising from the Company's proprietary Post-Traumatic Stress Disorder ("PTSD") programme, whose lead candidate is SVN-114.

Key Highlights

·      'Gold standard' pharmaceutical IP: the EPO allowance covers composition-of-matter claims, widely regarded as the strongest form of pharmaceutical patent protection.

·      Large market: PTSD affects an estimated 15.8 million people across the U.S., UK, EU4 and Japan.

·      Relevant sector benchmark: Otsuka's US$1.225 billion acquisition of PTSD-focused Transcend Therapeutics highlights the strategic value being placed on next-generation PTSD treatments.

·      Broader protection around SVN-114: the allowance adds to the proprietary chemistry estate supporting Solvonis' lead PTSD candidate.

·      Next-generation profile: SVN-114 is designed to improve on current PTSD treatments in development, with the aim of reducing cardiovascular burden and abuse potential and shortening the treatment window.

Strengthening the IP around SVN-114

SVN-114 is Solvonis' proprietary lead candidate for PTSD and related trauma-associated disorders and is contained within its own core patent-pending family.

The Company has also developed three additional chemically distinct supporting patent families through its PTSD programme. Following the latest European allowance, each of these three families has now achieved composition-of-matter grant or allowance in the U.S. or Europe, broadening the proprietary IP estate supporting the programme.

Composition-of-matter patents protect novel chemical compounds themselves, rather than only a particular formulation or therapeutic use, and are widely regarded as the strongest form of pharmaceutical IP protection.

Standard EPO formalities will now be completed prior to formal grant. A corresponding U.S. application remains pending, while examination has also been requested in Canada.

A large and increasingly strategic PTSD market

PTSD represents a significant unmet medical need, affecting an estimated 15.8 million people across the U.S., UK, EU4 and Japan, with limited approved pharmacological treatment options.

The strategic relevance of the market was highlighted in June 2026 when Otsuka Pharmaceutical acquired Transcend Therapeutics for US$700 million upfront and up to US$525 million in contingent consideration.

Transcend's lead asset, methylone-based TSND-201, is in Phase 3 development for PTSD following positive Phase 2 results, providing a relevant clinical and commercial benchmark for this emerging class of PTSD treatments.

SVN-114 is designed as a next-generation approach to this class. Its differentiated pharmacological profile is intended to reduce cardiovascular and abuse-liability risks, while its soft-drug design targets faster metabolism and a shorter, more predictable treatment window.

If demonstrated clinically, these characteristics could support improved tolerability and a more practical and scalable supervised-treatment model. These potential advantages remain to be established through further preclinical and clinical development.

More broadly, Eli Lilly's agreed acquisition of AtaiBeckley for up to US$3.8 billion further demonstrates pharmaceutical investment in next-generation neuropsychiatry assets.

Next Steps

Solvonis intends to progress SVN-114 through further pharmacology, pharmacokinetic and brain-exposure studies, safety pharmacology and formal abuse-liability assessment.

Consistent with its capital-efficient development model, the Company intends to seek non-dilutive grant and research funding in the UK, European Union and United States to advance SVN-114 towards IND-enabling development.

Anthony Tennyson, Chief Executive Officer, commented: "This allowance strengthens the proprietary position around SVN-114 in a large PTSD market attracting significant pharmaceutical investment. We believe its differentiated profile and broad IP estate provide a strong foundation for long-term value creation."

Professor David Nutt, Chief Scientific Officer, added: "The clinical progress of new treatments being developed for PTSD provides important validation for this therapeutic approach. SVN-114 has been designed to take that approach further, with a differentiated profile intended to support faster metabolism and a shorter, more predictable treatment window. This European allowance further strengthens the proprietary position around the programme as we advance its development."

Enquiries

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
[e-mail]

Turner Pope Investments (TPI) Limited
Corporate Broker
Andrew Thacker / Guy McDougall
[phone]

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system ("CNS") disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.

The Company's lead programmes target Alcohol Use Disorder ("AUD") and Post-Traumatic Stress Disorder ("PTSD"), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is being advanced towards a planned Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company's PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain-signalling systems associated with emotional processing and social behaviour.

SVN-015 is the Company's proprietary discovery-stage candidate targeting stimulant use disorder. Following encouraging initial cardiac ion-channel and broader off-target screening results, it is advancing into further preclinical evaluation under NIDA's Addiction Treatment Discovery Program.

In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library and AI-enabled discovery capabilities to identify new small-molecule modulators of key neurotransmitter systems.

solvonis.com | LinkedIn |X

 

END